Regeneron Reports Phase 3 extension Data for Bictegravir in Marginal zone lymphoma

Regeneron today announced Phase 3 extension results for Bictegravir in patients with Marginal zone lymphoma. The study demonstrated that Bictegravir demonstrates favorable safety profile compared to standard of care or placebo. These results provide important insights into the treatment of Marginal zone lymphoma and support the continued development of Bictegravir in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Bictegravir was consistent with previous observations, with no new safety signals identified.